Tempus AI Stock Rises 0.98% as 205th Most Traded in U.S. Markets Following Groundbreaking Pancreatic Cancer Diagnostic Study

On September 9, 2025, , . The stock ranked 205th in volume among U.S. equities. A key development driving market attention is the publication of a clinical study in JCO Precision Oncology, which validates the PurIST® algorithmic diagnostic for pancreatic ductal adenocarcinoma (PDAC) treatment optimization.

The study, conducted by Tempus in collaboration with GeneCentric, demonstrates PurIST’s ability to classify PDAC tumors into "classical" or "basal" subtypes using RNA sequencing. This classification helps clinicians personalize chemotherapy regimens—either FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)—based on tumor subtype. For classical subtype patients with good performance status, . The findings position PurIST as a dual-purpose biomarker, offering both prognostic and predictive value in advanced PDAC management.

Tempus, a leader in AI-driven , emphasized the significance of the study in addressing a critical unmet need in oncology. The company’s xR RNA sequencing platform enabled real-world analysis of 931 advanced PDAC patients, reinforcing PurIST’s clinical utility. Executives highlighted the potential for the diagnostic to improve survival outcomes by guiding therapy selection, though broader adoption will depend on integration into standard clinical workflows.

Backtesting limitations persist due to current tool constraints. A rigorous evaluation requires access to market-wide volume rankings and end-of-day pricing data for the top 500 securities, which are not available in the current workspace. Alternative approaches include narrowing the universe to a predefined list of tickers or using liquid ETF proxies. The feasibility of these options will determine the next steps in validating Tempus’s market performance metrics.